.Pharmacolibrary.Drugs.D_Dermatologicals.D02B_ProtectivesAgainstUvRadiation.D02BB02_Afamelanotide.Afamelanotide .Pharmacolibrary.Drugs.D_Dermatologicals.D02B_ProtectivesAgainstUvRadiation.D02BB02_Afamelanotide.Afamelanotide| name: | Afamelanotide | |
| ATC code: | D02BB02 | |
| route: | subcutaneous | |
| compartments: | 1 | |
| dosage: | 16 | mg |
| volume of distribution: | 60 | L |
| clearance: | 2 | L/h |
| other parameters in model implementation | ||
Afamelanotide is a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH) used for the treatment of erythropoietic protoporphyria (EPP) to reduce photosensitivity and phototoxic reactions. It is administered as a subcutaneous implant and is approved for use in the European Union, Australia, and the United States.
Estimated pharmacokinetic parameters in healthy adults based on available public summaries and regulatory documents. No full peer-reviewed population PK modeling study available.